-       Report 
   - May 2022
    -  32 Pages 
    Global
   
   From       €400EUR$478USD£363GBP 
                -       Report 
   - November 2022
    -  154 Pages 
    Global
   
   From       €4487EUR$5,000USD£3,938GBP 
                  -       Report 
   - November 2025
     Global
   
   From       €750EUR$895USD£681GBP 
                  -       Report 
   - November 2025
     Global
   
   From       €600EUR$716USD£545GBP 
                  -       Report 
   - November 2025
     Global
   
   From       €600EUR$716USD£545GBP 
                   -       Report 
   - November 2025
     Global
   
   From       €450EUR$537USD£409GBP 
                  -       Report 
   - November 2025
     Global
   
   From       €200EUR$239USD£182GBP 
                -       Report 
   - July 2024
    -  266 Pages 
    Global
   
   From       €4442EUR$4,950USD£3,898GBP 
                -       Report 
   - July 2024
    -  335 Pages 
    Global
   
   From       €4442EUR$4,950USD£3,898GBP 
                  -       Report 
   - November 2024
    -  240 Pages 
    Global
   
   From       €1723EUR$1,920USD£1,512GBP 
      €2154EUR$2,400USD£1,890GBP 
                  -       Report 
   - May 2024
    -  420 Pages 
    Global
   
   From       €2154EUR$2,400USD£1,890GBP 
      €2692EUR$3,000USD£2,363GBP 
                  -       Report 
   - December 2023
    -  220 Pages 
    Global
   
   From       €2369EUR$2,640USD£2,079GBP 
      €2961EUR$3,300USD£2,599GBP 
                  -       Report 
   - October 2023
    -  420 Pages 
    Global
   
   From       €2082EUR$2,320USD£1,827GBP 
      €2602EUR$2,900USD£2,284GBP 
                  -       Report 
   - June 2022
    -  1500 Pages 
    Global
   
   From       €2800EUR$3,120USD£2,457GBP 
      €3500EUR$3,900USD£3,071GBP 
                  -       Drug Pipelines 
   - May 2022
    -  400 Pages 
    Global
   
   From       €2154EUR$2,400USD£1,890GBP 
      €2692EUR$3,000USD£2,363GBP 
                  -       Report 
   - November 2021
    -  222 Pages 
    Global
   
   From       €2154EUR$2,400USD£1,890GBP 
      €2692EUR$3,000USD£2,363GBP 
                -       Report 
   - October 2024
    -  181 Pages 
    Global
   
   From       €4173EUR$4,650USD£3,662GBP 
                -       Report 
   - December 2021
    -  353 Pages 
    Global
   
   From       €4935EUR$5,500USD£4,332GBP 
                -       Report 
   - July 2024
    -  100 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - September 2023
    -  98 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
             
         Car T therapies are a type of immunotherapy used to treat certain types of cancer. They involve the use of genetically modified T cells, which are a type of white blood cell, to recognize and attack cancer cells. The T cells are taken from the patient's blood, modified in a laboratory, and then infused back into the patient's body. This type of therapy has been used to treat certain types of leukemia and lymphoma, and is being studied for use in other types of cancer.
Car T therapies are a    relatively new type of oncology drug, and the market is still in its early stages. However, the potential of this type of therapy has led to a surge of interest from pharmaceutical companies, investors, and researchers. Companies are investing in research and development to improve the safety and efficacy of these therapies, as well as to expand their use to other types of cancer.
Some of the companies in the Car T therapies market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Celgene. Show Less   Read more